US 12,103,917 B2
Modulators of myocyte lipid accumulation and insulin resistance and methods of use thereof
Daniel Kelly, Philadelphia, PA (US); Richard Vega, Orlando, FL (US); Hampton Sessions, Orlando, FL (US); Teresa Leone, Philadelphia, PA (US); Byungyong Ahn, Wallingford, PA (US); and Satyamaheshwar Peddibhotla, Orlando, FL (US)
Assigned to THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, Philadelphia, PA (US)
Filed by THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, Philadelphia, PA (US)
Filed on Jun. 8, 2021, as Appl. No. 17/342,187.
Application 17/342,187 is a division of application No. 15/748,515, granted, now 11,028,061, previously published as PCT/US2016/044269, filed on Jul. 27, 2016.
Claims priority of provisional application 62/197,534, filed on Jul. 27, 2015.
Prior Publication US 2021/0300882 A1, Sep. 30, 2021
Int. Cl. C07D 277/46 (2006.01); A61K 31/426 (2006.01); A61K 31/428 (2006.01); A61K 31/4439 (2006.01); A61K 31/454 (2006.01); A61K 31/496 (2006.01); A61K 31/5375 (2006.01); A61K 31/5377 (2006.01); A61K 31/541 (2006.01); A61K 45/06 (2006.01); A61P 3/04 (2006.01); A61P 3/10 (2006.01); C07D 277/82 (2006.01); C07D 295/185 (2006.01); C07D 417/04 (2006.01); C07D 417/12 (2006.01)
CPC C07D 277/46 (2013.01) [A61K 31/426 (2013.01); A61K 31/428 (2013.01); A61K 31/4439 (2013.01); A61K 31/454 (2013.01); A61K 31/496 (2013.01); A61K 31/5375 (2013.01); A61K 31/5377 (2013.01); A61K 31/541 (2013.01); A61K 45/06 (2013.01); A61P 3/04 (2018.01); A61P 3/10 (2018.01); C07D 277/82 (2013.01); C07D 295/185 (2013.01); C07D 417/04 (2013.01); C07D 417/12 (2013.01)] 12 Claims
 
1. A pharmaceutical composition comprising
(i) a compound represented by the general Formula IX:

OG Complex Work Unit Chemistry
wherein
Ri′ and R2′ are independently hydrogen, substituted heterocyclyl, unsubstituted heterocyclyl, substituted alkyl, unsubstituted alkyl, substituted alkenyl, unsubstituted alkenyl, substituted alkynyl, unsubstituted alkynyl, substituted alkoxy, unsubstituted alkoxy, substituted amino, unsubstituted amino, substituted alkylamino, unsubstituted alkylamino, amide, substituted amide, carbonyl, substituted carbonyl, carboxyl, substituted carboxyl, substituted alkylthio, unsubstituted alkylthio, halogen, hydroxyl, nitro, cyano, or R1′ and R2′ combine to form substituted heterocyclyl or unsubstituted heterocyclyl;
R3′ is O—CH3; and
A is a substituted aryl, substituted heteroaryl, unsubstituted heteroaryl, substituted heterocyclyl, or unsubstituted heterocyclyl;
wherein the compound is not SBI-477; or
(ii) a combination of (i) and a Mondo inhibitor;
in an effective amount to reduce cellular triacylglycerol (TAG) levels and/or increase cellular glucose uptake in a subject.